INDBInternet News Database 2.5 Updated just now · 397 sources Show or hide images Light or dark

Caliway's CBL-514 Receives Early IND Clearance in China, Accelerating Development in the World's Fastest-Growing Body Contouring Market

Save Like Comments Compare coverage
Image from Amherst Bee

Summary

China Clinical Trial Cleared Ahead of Schedule—CBL-514's China clinical study (CBL-0102) received authorization to proceed from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) ahead of the anticipated timeline, reflecting regulatory recognition of the study…

Description from Amherst Bee.

Who is covering this

  1. Amherst Bee Not rated US
    Caliway's CBL-514 Receives Early IND Clearance in China, Accelerating Development in the World's Fastest-Growing Body Contouring Market

    China Clinical Trial Cleared Ahead of Schedule—CBL-514's China clinical study (CBL-0102) received authorization to proceed from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) ahead of the anticipated timeline, reflecting...

Comments

Comments need JavaScript.